Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Cash & Equivalents (2016 - 2025)

Celldex Therapeutics has reported Cash & Equivalents over the past 16 years, most recently at $28.9 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $28.9 million for Q4 2025, up 1.82% from a year ago — trailing twelve months through Dec 2025 was $28.9 million (up 1.82% YoY), and the annual figure for FY2025 was $28.9 million, up 1.82%.
  • Cash & Equivalents for Q4 2025 was $28.9 million at Celldex Therapeutics, down from $36.0 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CLDX hit a ceiling of $115.1 million in Q1 2024 and a floor of $17.1 million in Q1 2025.
  • Median Cash & Equivalents over the past 5 years was $32.1 million (2022), compared with a mean of $39.6 million.
  • Biggest five-year swings in Cash & Equivalents: surged 297.69% in 2021 and later crashed 85.11% in 2025.
  • Celldex Therapeutics' Cash & Equivalents stood at $39.1 million in 2021, then fell by 24.82% to $29.4 million in 2022, then rose by 18.3% to $34.8 million in 2023, then decreased by 18.55% to $28.4 million in 2024, then increased by 1.82% to $28.9 million in 2025.
  • The last three reported values for Cash & Equivalents were $28.9 million (Q4 2025), $36.0 million (Q3 2025), and $23.0 million (Q2 2025) per Business Quant data.